GSK PLC (GSK) reports robust sales and profit growth, while navigating external pressures in the vaccine market and preparing for future product approvals.
Hosted on MSN20h
GSK stays optimistic on vaccines amidst US and China woesWhile vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
Investor's Business Daily on MSN22h
GSK Surges 8% After Bumping Its 2031 Outlook To North Of $50 BillionGSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback